224 related articles for article (PubMed ID: 22767340)
1. A reduction in between subject variability is not mandatory for selecting a new covariate.
Lagishetty CV; Vajjah P; Duffull SB
J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):383-92. PubMed ID: 22767340
[TBL] [Abstract][Full Text] [Related]
2. Assessment of type I error rates for the statistical sub-model in NONMEM.
Wählby U; Bouw MR; Jonsson EN; Karlsson MO
J Pharmacokinet Pharmacodyn; 2002 Jun; 29(3):251-69. PubMed ID: 12449498
[TBL] [Abstract][Full Text] [Related]
3. The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion.
Silber HE; Kjellsson MC; Karlsson MO
J Pharmacokinet Pharmacodyn; 2009 Feb; 36(1):81-99. PubMed ID: 19219538
[TBL] [Abstract][Full Text] [Related]
4. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.
Ribbing J; Jonsson EN
J Pharmacokinet Pharmacodyn; 2004 Apr; 31(2):109-34. PubMed ID: 15379381
[TBL] [Abstract][Full Text] [Related]
5. Investigating the contribution of residual unexplained variability components on bias and imprecision of parameter estimates in population pharmacokinetic mixed-effects modeling.
Jaber MM; Brundage RC
J Pharmacokinet Pharmacodyn; 2023 Apr; 50(2):123-132. PubMed ID: 36617366
[TBL] [Abstract][Full Text] [Related]
6. Design of pharmacokinetic studies for latent covariates.
Lagishetty CV; Coulter CV; Duffull SB
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):87-97. PubMed ID: 22161222
[TBL] [Abstract][Full Text] [Related]
7. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
[TBL] [Abstract][Full Text] [Related]
8. Assessment of actual significance levels for covariate effects in NONMEM.
Wählby U; Jonsson EN; Karlsson MO
J Pharmacokinet Pharmacodyn; 2001 Jun; 28(3):231-52. PubMed ID: 11468939
[TBL] [Abstract][Full Text] [Related]
9. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.
Hennig S; Norris R; Kirkpatrick CM
Br J Clin Pharmacol; 2008 Apr; 65(4):502-10. PubMed ID: 17995972
[TBL] [Abstract][Full Text] [Related]
10. Operating characteristics of stepwise covariate selection in pharmacometric modeling.
Ahamadi M; Largajolli A; Diderichsen PM; de Greef R; Kerbusch T; Witjes H; Chawla A; Davis CB; Gheyas F
J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):273-285. PubMed ID: 31020450
[TBL] [Abstract][Full Text] [Related]
11. Implications of choosing a correlation structure on model selection and parameter estimation.
Jain L; Jadhav P; Gobburu J
Int J Clin Pharmacol Ther; 2014 Jul; 52(7):598-611. PubMed ID: 24725444
[TBL] [Abstract][Full Text] [Related]
12. Covariate detection in population pharmacokinetics using partially linear mixed effects models.
Bonate PL
Pharm Res; 2005 Apr; 22(4):541-9. PubMed ID: 15846461
[TBL] [Abstract][Full Text] [Related]
13. Concordance between criteria for covariate model building.
Hennig S; Karlsson MO
J Pharmacokinet Pharmacodyn; 2014 Apr; 41(2):109-25. PubMed ID: 24599695
[TBL] [Abstract][Full Text] [Related]
14. The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data.
Tunblad K; Lindbom L; McFadyen L; Jonsson EN; Marshall S; Karlsson MO
J Pharmacokinet Pharmacodyn; 2008 Oct; 35(5):503-26. PubMed ID: 19011957
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
16. Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides.
Matthews I; Kirkpatrick C; Holford N
Br J Clin Pharmacol; 2004 Jul; 58(1):8-19. PubMed ID: 15206987
[TBL] [Abstract][Full Text] [Related]
17. Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building.
Sherer EA; Sale ME; Pollock BG; Belani CP; Egorin MJ; Ivy PS; Lieberman JA; Manuck SB; Marder SR; Muldoon MF; Scher HI; Solit DB; Bies RR
J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):393-414. PubMed ID: 22767341
[TBL] [Abstract][Full Text] [Related]
18. Estimation of lithium clearance from routine clinical data in Egyptian bipolar patients. A population pharmacokinetic approach.
ElDesoky ES; Kumar V; Alorainy MS; Hamdi MM; Derendorf H
Int J Clin Pharmacol Ther; 2008 Dec; 46(12):617-26. PubMed ID: 19049695
[TBL] [Abstract][Full Text] [Related]
19. Adjusted adaptive Lasso for covariate model-building in nonlinear mixed-effect pharmacokinetic models.
Haem E; Harling K; Ayatollahi SM; Zare N; Karlsson MO
J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):55-66. PubMed ID: 28144841
[TBL] [Abstract][Full Text] [Related]
20. [Effects of multiple-trough sampling design and algorithm on the estimation of population and individual pharmacokinetic parameters].
Ling J; Qian LX; Ding JJ; Jiao Z
Yao Xue Xue Bao; 2014 May; 49(5):686-94. PubMed ID: 25151742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
